Umeclidinium/Vilanterol 62.5/25 mcg

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Pulmonary Disease, Chronic Obstructive

Drug Information

Target Indication

Pulmonary Disease, Chronic Obstructive

Clinical Trial

Last updated: 1/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Related Pipeline

Acute Coronary Syndrome

Dental Caries

Thromboembolism

Pulmonary Disease, Chronic Obstructive

Hepatitis B